Passage BIO, Inc. (PASG) stock
PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.25+0.24 (+5.99%)
Close on Nov 13, 2026Market cap $13.68MP/E –Yield –
Passage BIO cash
Cash and short-term investments held at the end of each period.
Passage BIO's cash was $20.16M at Sep 30, 2026. For fiscal 2025 it was $46.30M, down 39.7% from the year before. The highest annual figure on record is $315.77M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.30M | -39.7% |
| FY2024 | Dec 31, 2024 | $76.76M | -32.8% |
| FY2023 | Dec 31, 2023 | $114.29M | -39.7% |
| FY2022 | Dec 31, 2022 | $189.61M | -40.0% |
| FY2021 | Dec 31, 2021 | $315.77M | +3.6% |
| FY2020 | Dec 31, 2020 | $304.82M | +91.9% |
| FY2019 | Dec 31, 2019 | $158.87M | +539.0% |
| FY2018 | Dec 31, 2018 | $24.86M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $20.16M | -61.8% |
| Q2 FY2026 | Jun 30, 2026 | $24.16M | -58.1% |
| Q1 FY2026 | Mar 31, 2026 | $33.34M | -47.4% |
| Q4 FY2025 | Dec 31, 2025 | $46.30M | -39.7% |
| Q3 FY2025 | Sep 30, 2025 | $52.77M | -37.8% |
| Q2 FY2025 | Jun 30, 2025 | $57.63M | -37.2% |
| Q1 FY2025 | Mar 31, 2025 | $63.36M | -39.4% |
| Q4 FY2024 | Dec 31, 2024 | $76.76M | -32.8% |
| Q3 FY2024 | Sep 30, 2024 | $84.83M | -36.1% |
| Q2 FY2024 | Jun 30, 2024 | $91.77M | -39.4% |
| Q1 FY2024 | Mar 31, 2024 | $104.53M | -37.7% |
| Q4 FY2023 | Dec 31, 2023 | $114.29M | -39.7% |
| Q3 FY2023 | Sep 30, 2023 | $132.78M | -37.9% |
| Q2 FY2023 | Jun 30, 2023 | $151.48M | -36.7% |
| Q1 FY2023 | Mar 31, 2023 | $167.77M | -37.2% |
| Q4 FY2022 | Dec 31, 2022 | $189.61M | -40.0% |
| Q3 FY2022 | Sep 30, 2022 | $213.76M | -39.7% |
| Q2 FY2022 | Jun 30, 2022 | $239.25M | -41.3% |
| Q1 FY2022 | Mar 31, 2022 | $267.09M | -39.0% |
| Q4 FY2021 | Dec 31, 2021 | $315.77M | +3.6% |
| Q3 FY2021 | Sep 30, 2021 | $354.40M | +5.6% |
| Q2 FY2021 | Jun 30, 2021 | $407.80M | +15.4% |
| Q1 FY2021 | Mar 31, 2021 | $437.59M | +19.3% |
| Q4 FY2020 | Dec 31, 2020 | $304.82M | +91.9% |
| Q3 FY2020 | Sep 30, 2020 | $335.70M | +89.5% |
| Q2 FY2020 | Jun 30, 2020 | $353.42M | +348.6% |
| Q1 FY2020 | Mar 31, 2020 | $366.83M | +735.2% |
| Q4 FY2019 | Dec 31, 2019 | $158.87M | +539.0% |
| Q3 FY2019 | Sep 30, 2019 | $177.19M | – |
| Q2 FY2019 | Jun 30, 2019 | $78.79M | – |
| Q1 FY2019 | Mar 31, 2019 | $43.92M | – |
| Q4 FY2018 | Dec 31, 2018 | $24.86M | – |
See a number that looks wrong?